Guru Subramanian Guru Murthy, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the findings of a retrospective study investigating whether allogeneic hematopoietic cell transplantation (alloHCT) with younger HLA-matched unrelated donors is associated with superior disease-free survival (DFS) for patients with myelodysplastic syndromes (MDS) when compared with older HLA-identical sibling donors. The study, which analyzed data from 1761 patients, found superior DFS for MDS patients undergoing alloHCT from younger HLA-matched unrelated donors compared to older HLA-identical sibling donors. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.